Human Immunodeficiency Virus (HIV) is a chronic and life-threatening infectious disease, which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus that attacks immune cells known as CD-4 cells, further lowering the immunity. Rising prevalence of HIV is prompting the need for effective anti-HIV drugs.
Anti-HIV drugs help in preventing the multiplication of the HIV virus, thereby reducing the risk of transmission. Currently, HIV is treated using drugs belonging to classes such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs). Some of the prominent drugs available in the market include Truvada, Atripla, Stribild, and Prezista/Prezcobix. The anti-HIV drug market’s most prominent driver is the rising government initiative to awareness regarding the causes, symptoms, and treatments of HIV. Additionally, the introduction of cost-effective generic drugs drives the market growth.
Got questions about your regional growth of
Anti-HIV Drugs Market?
Just drop us a line or call on +1 646 480 7505
Anti-HIV Drugs Market Segmentation
By Medication Class
By Distribution Channel
" Crucial Insights The Report Provides:"
* Known and Unknown Adjacencies Influencing the Growth of Market
* Explorable Revenue Sources
* Customer Behaviour Analysis
* Target Partners
* Customized Geographical Data Based on Customers as well as Competitors
* Analysis of Market Size and CAGR between the Forecast PeriodsView Full Report Buy This Report Now